4//SEC Filing
Isett Thomas Francis 3rd 4
Accession 0001638599-20-000336
CIK 0001420720other
Filed
Mar 22, 8:00 PM ET
Accepted
Mar 23, 11:19 AM ET
Size
14.1 KB
Accession
0001638599-20-000336
Insider Transaction Report
Form 4
iBio, Inc.IBIO
Isett Thomas Francis 3rd
Director
Transactions
- Exercise of In-Money
Series B Warrants (Right to Buy)
2020-03-17$1000.00/sh+78,024$78,024,000→ 1,275,000 totalExercise: $0.22From: 2019-10-29Exp: 2026-10-29→ Common Stock (78,024 underlying) - Conversion
Common Stock
2020-03-19$0.20/sh+100,000$20,000→ 1,275,000 total - Exercise of In-Money
Common Stock
2020-03-17$0.22/sh+78,024$17,165→ 1,275,000 total - Conversion
Series C Convertible Preferred Stock
2020-03-19$1000.00/sh+20$20,000→ 1,275,000 totalExercise: $0.20→ Common Stock (100,000 underlying)
Footnotes (9)
- [F1]The shares of Series C Convertible Preferred Stock were acquired by Mr. Isett in a public offering by iBio, Inc. ("iBio").
- [F2]Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion.
- [F3]The Series C Preferred Shares have no expiration date.
- [F4]Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.
- [F5]Reflects number of securities beneficially owned following all transactions reported on this Form 4.
- [F6]The Series B Warrants were acquired by Mr. Isett in a public offering by iBio.
- [F7]The Series B Warrants were sold together with Series C Preferred Shares and Series A Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.
- [F8]100,000 shares of common stock were issued to Mr. Isett upon conversion of 20 shares of Series C Convertible Preferred Stock at a conversion price of $0.20 per share in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock. The shares of Series C Convertible Preferred Stock were acquired by Mr. Isett in a public offering by iBio.
- [F9]78,024 shares of common stock were issued to Mr. Isett upon exercise of Series B Warrants at an exercise price of $0.22 per share accordance with the terms of the Series B Warrants. The Series B Warrants were acquired by Mr. Isett in a public offering by iBio, Inc.
Documents
Issuer
iBio, Inc.
CIK 0001420720
Entity typeother
Related Parties
1- filerCIK 0001773100
Filing Metadata
- Form type
- 4
- Filed
- Mar 22, 8:00 PM ET
- Accepted
- Mar 23, 11:19 AM ET
- Size
- 14.1 KB